Showing 4,001 - 4,020 results of 30,932 for search '(( 50 ((nn decrease) OR (((a decrease) OR (mean decrease)))) ) OR ( 2 step decrease ))', query time: 1.07s Refine Results
  1. 4001

    50 µM resveratrol is toxic to C<sub>2</sub>C<sub>12</sub> myotubes. by Kazuhiko Higashida (351645)

    Published 2013
    “…<p>(A) Exposure to 50 µM resveratrol (RSV) for 24 h is toxic to C<sub>2</sub>C<sub>12</sub> myotubes resulting in a decrease in viable cells and (B) a decrease in ATP content. …”
  2. 4002
  3. 4003
  4. 4004
  5. 4005
  6. 4006

    Svaldi et al.’s “High Load” and “Low Load” groups from a soccer season (High Load percentiles: 25th = 4515 g, 50th = 5615 g, 75th = 12313 g; Low Load percentiles: 25th = 2425 g, 50... by Joshua Auger (9530081)

    Published 2020
    “…<p>Post-season adjustments to the High Load group: 19.7% reduction from decreasing inflation pressure from 1.10 bar (16 psi) to 0.55 bar (8 psi), 7.1% reduction from downsizing a size 5, 0.55 bar (8 psi) ball to size 4.5, 0.55 bar (8 psi) ball (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0240162#pone.0240162.t003" target="_blank">Table 3</a>), and a 20% reduction in number of hits based on average PLA per hit (Adjusted High Load percentiles: 25th = 2463 g, 50th = 3063 g, 75th = 6718 g).…”
  7. 4007
  8. 4008
  9. 4009
  10. 4010
  11. 4011
  12. 4012
  13. 4013
  14. 4014

    Image2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  15. 4015

    Image1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIFF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  16. 4016

    Image3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  17. 4017
  18. 4018
  19. 4019
  20. 4020